Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19814180 | 1.00 | CPB1 (0.50) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL6342264 | 1.00 | CPB1 (0.50) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL13404519 | 1.00 | CPB1 (0.50) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL13404520 | 0.93 | CPB1 (0.49) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL6356119 | 0.93 | HSD11B1 (0.49) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL3552331 | 0.92 | CPB1 (0.59) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL12895664 | 0.92 | CPB1 (0.59) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL12884056 | 0.92 | CPB1 (0.59) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL12992940 | 0.92 | CPB1 (0.59) | CPB1HSD11B1JAK2JAK1GPR119 | |
| SCHEMBL29541951 | 0.92 | CPB1 (0.59) | CPB1HSD11B1JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110563717-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-7825139-B2 | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV | Forest Laboratories Holdings Limited (BM) | 2010-11-02 | — | — | US | disclosed |
| US-7825139-B2 | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV | Forest Laboratories Holdings Limited (BM) | 2010-11-02 | — | — | US | disclosed |
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | Forest Laboratories Holding Limited (BM) | 2006-12-07 | — | — | US | disclosed |
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | Forest Laboratories Holding Limited (BM) | 2006-12-07 | — | — | US | disclosed |
| US-6949546-B2 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP3, DPP7 | CPB1 76/4885HSD11B1 188/4885JAK2 1685/4885 |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CPB1 919/4885HSD11B1 1213/4885JAK2 1616/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | CPB1 919/4885HSD11B1 1213/4885JAK2 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.